Skip to content

Joshua Mitchell

2 papers in the library · 1 citation · publishing 2026

Papers

Sort Most recent Most cited

When Off-Label Ketamine Meets Direct-to-Consumer Telehealth: Liability Risks and Ethical Responsibilities.

Psychiatric services (Washington, D.C.) July 1, 2026 Joshua Mitchell, Benjamin Bregman, Renuka Surujnarain et al.

Aided by COVID-19-era regulatory flexibilities, direct-to-consumer telemedicine has expanded access to mental health care. Ketamine prescribed off-label for psychiatric conditions is increasingly marketed online and delivered at home through telehealth platforms. Taking a wrongful death lawsuit against a telehealth ketamine provider as a point of departure, the authors examine how combining...

From trials to clinics: investigators’ perspectives on translating psychedelic research into clinical care

Translational Behavioral Medicine 2026 Joshua Mitchell, Logan Neitzke-Spruill, David S. Mathai et al. 1 citation

BACKGROUND: Psychedelics such as 3,4-methylenedioxymethamphetamine (MDMA) and psilocybin are showing promising results in clinical trials for the treatment of mental health disorders, including post-traumatic stress disorder, addiction, and treatment-resistant depression. US Food and Drug Administration approval may be on the horizon. Yet, little is known about how these treatments will move...